Viva Biotech expands its reach with a new branch in Boston
- Viva Biotech has established a new branch in Boston to bolster its global expansion strategy.
- The Boston location will serve as a crucial hub for connecting operations in various regions, including China and Europe.
- This move is expected to enhance the company's market presence and strengthen capabilities in the North American biopharmaceutical sector.
In a significant development in the biopharmaceutical sector, Viva Biotech Holdings Group has officially established a new branch in Boston, USA. This strategic decision came on December 11, 2024, as part of the company's broader global expansion initiative. Boston is recognized as a leading hub for biopharmaceutical innovation, with its ecosystem offering unparalleled resources for drug discovery and development, making it a prime location for Viva Biotech's enhanced operations. The Boston branch, located in Cambridge, Massachusetts, is set to serve as a pivotal hub within Viva Biotech's global network. This move aims to strengthen the company's market coverage and service capabilities in North America, responding effectively to the increasing demands in the biopharmaceutical industry. The interconnected operations between Boston and Viva Biotech's branches in China, the UK, Europe, and elsewhere reflect the company's commitment to fostering a responsive operational system in the evolving landscape of drug development. Dr. Cheney Mao, the Chairman and CEO, emphasized the importance of Boston in terms of innovation within the biopharmaceutical field. He noted that establishing a branch in Boston is a critical step in deepening their presence in international markets and enhancing competitiveness globally. Furthermore, the company's plans to expand both its Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services highlight a strategic focus on strengthening early-stage project capabilities, which is essential for future growth. Additionally, Dr. Derek Ren, CEO of Viva Biotech (Shanghai), remarked that the Boston branch not only lays a foundation for the business layout but also serves as a key connection to innovation resources globally. Through this new establishment, Viva Biotech aims to provide advanced drug discovery services and support high-potential startups through its equity for service (EFS) model, ensuring that unmet medical needs are adequately addressed and bolstering the global biopharmaceutical industry.